#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA2050694	B	Inhibition of HCV NS5A assessed as antiviral activity against HCV by viral replicon assay	Hepatitis C virus	20	ALA2046362	single protein format	Scientific Literature
2.	ALA3807264	B	Inhibition of HCV NS5A in Huh5-2 replicon cells at 100 uM propidium iodide staining based confocal microscopic analysis	Hepatitis C virus	1	ALA3804762	cell-based format	Scientific Literature
3.	ALA3829222	B	Inhibition of NS5A in HCV genotype 1a Y93H mutant assessed as replicon RNA levels by real time PCR based cell based assay	Hepatitis C virus subtype 1a	35	ALA3826948	cell-based format	Scientific Literature
4.	ALA3829319	B	Inhibition of NS5A in HCV genotype 1a L31V mutant assessed as replicon RNA levels by real time PCR based cell based assay	Hepatitis C virus subtype 1a	35	ALA3826948	cell-based format	Scientific Literature
5.	ALA3829326	B	Inhibition of NS5A in HCV genotype 1a Y93H mutant	Hepatitis C virus subtype 1a	2	ALA3826948	assay format	Scientific Literature
6.	ALA3829327	B	Inhibition of NS5A in HCV genotype 1a L31V mutant	Hepatitis C virus subtype 1a	2	ALA3826948	assay format	Scientific Literature
7.	ALA3855877	B	Inhibition of NS5A L31V mutant in HCV genotype 1a assessed as reduction in replicon RNA level after 3 days by cell based RT-PCR method	Hepatitis C virus subtype 1a	26	ALA3853354	cell-based format	Scientific Literature
8.	ALA3855878	B	Inhibition of NS5A Y93H mutant in HCV genotype 1a assessed as reduction in replicon RNA level after 3 days by cell based RT-PCR method	Hepatitis C virus subtype 1a	26	ALA3853354	cell-based format	Scientific Literature
9.	ALA3863058	B	Inhibition of HCV genotype 1a NS5A Y93H mutant after 3 day incubation by RT-PCR-cell-based HCV replicon assay	Hepatitis C virus subtype 1a	18	ALA3861993	cell-based format	Scientific Literature
10.	ALA3863059	B	Inhibition of HCV genotype 1a NS5A L31V mutant after 3 day incubation by RT-PCR-cell-based HCV replicon assay	Hepatitis C virus subtype 1a	18	ALA3861993	cell-based format	Scientific Literature
11.	ALA3878686	B	Inhibition of HCV genotype-1a NS5A Y93H mutant infected in human HuH7 cells by luciferase reporter gene assay	Hepatitis C virus subtype 1a	57	ALA3877294	cell-based format	Scientific Literature
12.	ALA3878688	B	Inhibition of HCV genotype-1a NS5A L31V mutant infected in human HuH7 cells by luciferase reporter gene assay	Hepatitis C virus subtype 1a	50	ALA3877294	cell-based format	Scientific Literature
13.	ALA3878692	B	Inhibition of HCV genotype-1b NS5A Y93H mutant infected in human HuH7 cells by luciferase reporter gene assay	Hepatitis C virus subtype 1b	2	ALA3877294	cell-based format	Scientific Literature
14.	ALA3878693	B	Inhibition of HCV genotype-1a NS5A Q30R mutant infected in human HuH7 cells by luciferase reporter gene assay	Hepatitis C virus subtype 1a	2	ALA3877294	cell-based format	Scientific Literature
15.	ALA3878694	B	Inhibition of HCV genotype-1a NS5A Y93C mutant infected in human HuH7 cells by luciferase reporter gene assay	Hepatitis C virus subtype 1a	2	ALA3877294	cell-based format	Scientific Literature
16.	ALA3888893	B	Luciferase Assay: The Huh-7 cells transfected with HCV replicons system were seeded into 96-well plates (8,000 cells in 125 μL/well) respectively; each test compound was diluted to desired concentration using 5-fold serial dilutions protocol, 10 doses in duplicate, and added to wells with POD™ 810 Plate Assembler. The plates were incubated in a CO2 incubator for 72 hours; after that, 40 μL of Luciferase assay substrate (Promega Bright-Glo) was added to each well, and detected by a chemiluminescence detection system (Topcount Microplate Scintillation and Luminescence Counter) 5 minutes later; the EC50 (half-maximal effective concentration, concentration for 50% of maximal effect) values of test compounds were analyzed by GraphPad Prism software, respectively. In this paper, experiments were repeated twice and set the holes without compounds as negative control.		34	ALA3886877	cell-based format	BindingDB Database
17.	ALA3888894	B	Luciferase Assay: The Huh-7 cells transfected with HCV replicons system were seeded into 96-well plates (8,000 cells in 125 μL/well) respectively; each test compound was diluted to desired concentration using 5-fold serial dilutions protocol, 10 doses in duplicate, and added to wells with POD™ 810 Plate Assembler. The plates were incubated in a CO2 incubator for 72 hours; after that, 40 μL of Luciferase assay substrate (Promega Bright-Glo) was added to each well, and detected by a chemiluminescence detection system (Topcount Microplate Scintillation and Luminescence Counter) 5 minutes later; the EC50 (half-maximal effective concentration, concentration for 50% of maximal effect) values of test compounds were analyzed by GraphPad Prism software, respectively. In this paper, experiments were repeated twice and set the holes without compounds as negative control.		34	ALA3886877	cell-based format	BindingDB Database
18.	ALA3888946	B	Transient Replicon Assay: In a transient set-up, a Huh-7 lunet hepatoma cell line was transiently transfected with an autonomously replicating RNA encoding a bi-cistronic expression construct. This construct comprises a firefly luciferase reporter gene preceding the NS3-NS5B subgenomic region of HCV (genotype 1a H77 or 1b Con1). Translation of the HCV subgenomic region is mediated by an internal ribosome entry site of encephalomyocarditis virus. The construct is furthermore flanked by 5' and 3' untranslated regions of HCV (genotype 1a H77 or 1b Con 1, respectively), which allow for replication of the RNA. In addition to the wild-type constructs, site-directed mutations were introduced into the transient HCV genotype 1b replicon in the gene encoding for the non-structural protein 5A (NS5A). More precisely, amino acid residues 28, 30, 31 and 93 in NS5A were independently altered. Cells were plated in 384 well plates in the presence of test and control compounds, which were added in various concentrations. Following an incubation of two days, replication of the HCV subgenomic replicon RNA was measured by assaying luciferase activity (using standard luciferase assay substrates and reagents and a Perkin Elmer ViewLux™ ultraHTS microplate imager). HCV subgenomic replicon containing cells in the control cultures have high luciferase expression in the absence of any inhibitor. The inhibitory activity of the compound was monitored, enabling a dose-response curve for each test compound.		11	ALA3886209	cell-based format	BindingDB Database
19.	ALA3888947	B	Transient Replicon Assay: In a transient set-up, a Huh-7 lunet hepatoma cell line was transiently transfected with an autonomously replicating RNA encoding a bi-cistronic expression construct. This construct comprises a firefly luciferase reporter gene preceding the NS3-NS5B subgenomic region of HCV (genotype 1a H77 or 1b Con1). Translation of the HCV subgenomic region is mediated by an internal ribosome entry site of encephalomyocarditis virus. The construct is furthermore flanked by 5' and 3' untranslated regions of HCV (genotype 1a H77 or 1b Con 1, respectively), which allow for replication of the RNA. In addition to the wild-type constructs, site-directed mutations were introduced into the transient HCV genotype 1b replicon in the gene encoding for the non-structural protein 5A (NS5A). More precisely, amino acid residues 28, 30, 31 and 93 in NS5A were independently altered. Cells were plated in 384 well plates in the presence of test and control compounds, which were added in various concentrations. Following an incubation of two days, replication of the HCV subgenomic replicon RNA was measured by assaying luciferase activity (using standard luciferase assay substrates and reagents and a Perkin Elmer ViewLux™ ultraHTS microplate imager). HCV subgenomic replicon containing cells in the control cultures have high luciferase expression in the absence of any inhibitor. The inhibitory activity of the compound was monitored, enabling a dose-response curve for each test compound.		11	ALA3886209	cell-based format	BindingDB Database
20.	ALA3888948	B	Transient Replicon Assay: In a transient set-up, a Huh-7 lunet hepatoma cell line was transiently transfected with an autonomously replicating RNA encoding a bi-cistronic expression construct. This construct comprises a firefly luciferase reporter gene preceding the NS3-NS5B subgenomic region of HCV (genotype 1a H77 or 1b Con1). Translation of the HCV subgenomic region is mediated by an internal ribosome entry site of encephalomyocarditis virus. The construct is furthermore flanked by 5' and 3' untranslated regions of HCV (genotype 1a H77 or 1b Con 1, respectively), which allow for replication of the RNA. In addition to the wild-type constructs, site-directed mutations were introduced into the transient HCV genotype 1b replicon in the gene encoding for the non-structural protein 5A (NS5A). More precisely, amino acid residues 28, 30, 31 and 93 in NS5A were independently altered. Cells were plated in 384 well plates in the presence of test and control compounds, which were added in various concentrations. Following an incubation of two days, replication of the HCV subgenomic replicon RNA was measured by assaying luciferase activity (using standard luciferase assay substrates and reagents and a Perkin Elmer ViewLux™ ultraHTS microplate imager). HCV subgenomic replicon containing cells in the control cultures have high luciferase expression in the absence of any inhibitor. The inhibitory activity of the compound was monitored, enabling a dose-response curve for each test compound.		11	ALA3886209	cell-based format	BindingDB Database